These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38001530)

  • 1. Homogeneous liquid-liquid microextraction coupled with HPLC/DAD for determination of nirmatrelvir and ritonavir as COVID-19 combination therapy in human plasma.
    Abdallah IA; Hammad SF; Bedair A; Mansour FR
    BMC Chem; 2023 Nov; 17(1):166. PubMed ID: 38001530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous quantification of nirmatrelvir and ritonavir by LC-MS/MS in patients treated for COVID-19.
    Martens-Lobenhoffer J; Böger CR; Kielstein J; Bode-Böger SM
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Dec; 1212():123510. PubMed ID: 36274268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous quantification of nirmatrelvir/ritonavir in human serum by LC-HRMS.
    Zhao F; Xiang Z; Han J; Pan J; Qu Y; Fan K; Wu Z; Xu D; Yu Y; Shen Z; Su C
    J Pharm Biomed Anal; 2024 Jan; 237():115796. PubMed ID: 37839266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous determination of nirmatrelvir and ritonavir in human plasma using LC-MS/MS and its pharmacokinetic application in healthy Chinese volunteers.
    Liu C; Zhu M; Cao L; Boucetta H; Song M; Hang T; Lu Y
    Biomed Chromatogr; 2022 Nov; 36(11):e5456. PubMed ID: 35881032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A UPLC-MS/MS Method for Plasma Biological Monitoring of Nirmatrelvir and Ritonavir in the Context of SARS-CoV-2 Infection and Application to a Case.
    Guyon J; Novion M; Fulda V; Ducint D; Molimard M; Couzi L; Kaminski H; Salvo F; Bouchet S
    J Am Soc Mass Spectrom; 2022 Oct; 33(10):1975-1981. PubMed ID: 36084269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Simple and Rapid LC-MS/MS Method for the Quantification of Nirmatrelvir/Ritonavir in Plasma of Patients with COVID-19.
    Zhu X; Li L; Dai B; Liu Z; Wang Z; Cui L; Gao S; Chen W; Tao X; Xu D
    Int J Anal Chem; 2024; 2024():6139928. PubMed ID: 38481558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjusted green HPLC determination of nirmatrelvir and ritonavir in the new FDA approved co-packaged pharmaceutical dosage using supported computational calculations.
    Imam MS; Batubara AS; Gamal M; Abdelazim AH; Almrasy AA; Ramzy S
    Sci Rep; 2023 Jan; 13(1):137. PubMed ID: 36599900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous green TLC determination of nirmatrelvir and ritonavir in the pharmaceutical dosage form and spiked human plasma.
    Imam MS; Abdelazim AH; Batubara AS; Gamal M; Almrasy AA; Ramzy S; Khojah H; Hasanin THA
    Sci Rep; 2023 Apr; 13(1):6165. PubMed ID: 37061601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants.
    Pagliano P; Spera A; Sellitto C; Scarpati G; Folliero V; Piazza O; Franci G; Conti V; Ascione T
    Expert Opin Drug Discov; 2023; 18(12):1301-1311. PubMed ID: 37614103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sugaring-out induced homogeneous liquid-liquid microextraction as an alternative mode for biological sample preparation: A comparative study.
    Abdallah IA; Hammad SF; Bedair A; Mansour FR
    J Sep Sci; 2021 Aug; 44(16):3117-3125. PubMed ID: 34101992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of favipiravir in human plasma using homogeneous liquid-liquid microextraction followed by HPLC/UV.
    Abdallah IA; Hammad SF; Bedair A; Elshafeey AH; Mansour FR
    Bioanalysis; 2022 Feb; 14(4):205-216. PubMed ID: 35001648
    [No Abstract]   [Full Text] [Related]  

  • 12. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
    Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
    Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19.
    Lemaitre F; Budde K; Van Gelder T; Bergan S; Lawson R; Noceti O; Venkataramanan R; Elens L; Moes DJAR; Hesselink DA; Pawinski T; Johnson-Davis KL; De Winter BCM; Pattanaik S; Brunet M; Masuda S; Langman LJ
    Ther Drug Monit; 2023 Apr; 45(2):191-199. PubMed ID: 35944126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
    Saravolatz LD; Depcinski S; Sharma M
    Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Saving lives with nirmatrelvir/ritonavir one transplant patient at a time".
    Belden KA; Yeager S; Schulte J; Cantarin MPM; Moss S; Royer T; Coppock D
    Transpl Infect Dis; 2023 Apr; 25(2):e14037. PubMed ID: 36847419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between M
    Dawood AA
    Adv Med Sci; 2023 Mar; 68(1):1-9. PubMed ID: 36368287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher sensitive selective spectrofluorometric determination of ritonavir in the presence of nirmatrelvir: application to new FDA approved co-packaged COVID-19 pharmaceutical dosage and spiked human plasma.
    Imam MS; Abdelazim AH; Ramzy S; Almrasy AA; Gamal M; Batubara AS
    BMC Chem; 2023 Sep; 17(1):120. PubMed ID: 37735663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paxlovid mouth likely is mediated by activation of the TAS2R1 bitter receptor by nirmatrelvir.
    Caronia L; Xi R; Margolskee RF; Jiang P
    Biochem Biophys Res Commun; 2023 Nov; 682():138-140. PubMed ID: 37806252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial.
    Yu Z; Zheng Y; Chen B; Lv J; Zhu X; Shang B; Xv Y; Tao R; Yang Y; Cong J; Li D; Wu H; Qv W; Zhang X; Xv C; Feng H; Yuan W; Gao Y
    Phytomedicine; 2023 Nov; 120():155025. PubMed ID: 37639813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.
    Marzolini C; Kuritzkes DR; Marra F; Boyle A; Gibbons S; Flexner C; Pozniak A; Boffito M; Waters L; Burger D; Back DJ; Khoo S
    Clin Pharmacol Ther; 2022 Dec; 112(6):1191-1200. PubMed ID: 35567754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.